Other Meetings

Other Meetings

On-site reporting from other meetings and summits in the hematology/oncology arena

On location

ELOQUENT-2: Adding Elotuzumab to Standard Therapy Reduces Progression Risk for Multiple Myeloma Patients

According to interim results of the phase III, randomized, open-label ELOQUENT-2 study, elotuzumab may offer a new treatment option for patients with relapsed multiple...
On location

Venetoclax Combined with Rituximab in Patients with Relapsed/Refractory CLL

An early-phase study of the combination of venetoclax, an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor, with rituximab showed response rates of 80 percent...
On location

Inotuzumab Ozogamicin Improves Complete Remission in Poor-Prognosis ALL

Inotuzumab ozogamicin (InO), an investigational anti-CD22 antibody drug conjugate, demonstrated a higher complete hematologic remission rate in adult patients with relapsed or refractory CD22-positive...
On location

High Response Rates for Brentuximab Vedotin Combinations in HL and DLBLC

High response rates were the hallmark of two clinical trials of brentuximab vedotin (BV) in combination with chemotherapy presented at the 2015 American Society...
On location

Treating the High-Risk APL Patient: ATRA + ATO + GO Might Be the Key

While the combinations of all-trans-retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA+ATO) and of ATRA+ATO plus gemtuzumab ozogamicin (GO; ATRA+ATO+GO) have yielded good clinical...
On location

In Multiple Myeloma, Carfilzomib Bests Bortezomib, But Bortezomib Bests Observation

Two multiple myeloma (MM) studies – one in relapsed disease and the other in newly diagnosed disease after autologous stem cell transplantation (ASCT) –...
On location

PI3K Inhibitors Safe and Effective in CLL Patients

Updated data on the safety and effectiveness of three different phosphoinositide 3-kinase inhibitors (PI3K inhibitors) presented at the European Hematology Association (EHA) Congress show...
On location

Single-Agent Ibrutinib Leads to Durable Responses in CLL

In both treatment-naïve and relapsed/refractory patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL), single-agent ibrutinib led to durable responses, according to...
On location

Pediatric Leukemia Patients May Benefit from CAR Therapy

Genetically reprogrammed T cells, which have been making waves in adult acute lymphocytic leukemia (ALL), have also shown promise in pediatric ALL patients, according...
On location

Updates on Novel Treatments for Leukemia

Three sessions at the American Association for Cancer Research Annual Meeting focused on promising, novel treatment options for patients with various forms of leukemia. In...
Advertisement

Current Issue

September 2020 Volume 6, Issue 11

This issue features a look at the evolution of preprint platforms, an analysis of the economic and health consequences of the COVID-19 pandemic, and more.

Block title